Moisturizing Creams Provide "Inadequate" UV Protection – Researchers
This article was originally published in The Tan Sheet
The top UV-containing moisturizing creams on the market inadequately deliver "broad spectrum" protection, with higher-priced formulas providing no advantage, according to researchers.
You may also be interested in...
FDA anticipates publishing its long-awaited final sunscreen monograph in the next several months, according to an agency spokeswoman. "FDA is working on the final rule for the testing and labeling of over-the-counter (OTC) sunscreens to address protection against UVB and UVA radiation," she wrote in an e-mail to "The Rose Sheet." In Department of Health and Human Services' semi-annual regulatory agenda published in April, FDA estimated it would issue the final monograph in October (1"The Rose Sheet" May 3, 2010). The monograph has been consistently delayed since the final rule first emerged in 1999, suspended in "regulatory limbo," according to the Environmental Working Group, one activist organization anxious for its release (2"The Rose Sheet" Oct. 4, 2010). FDA has been working its way through 3,000 public comments since the draft final rule was issued in 2007
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Dow Chemical, Anheuser-Busch and Kodak designate manufacturing for hand sanitizers and donate products to fight COVID-19. Dow is making up to 15 tons of sanitizer a day while Kodak donates formulas to New York's “NYS Clean” sanitizer distribution program.